The association between daily physical activity and plasma B-type natriuretic peptide in patients with glucose intolerance: A cross-sectional study

BMJ Open

Volumn 5, Issue 1, 2015, Pages

  Hamasaki, Hidetaka ^a,b   Yanai, Hidekatsu ^a   Kakei, Masafumi ^b   Noda, Mitsuhiko ^c   Ezaki, Osamu ^d  

^a National Center for Global Health and Medicine   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d SHOWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; HYPOCHOLESTEROLEMIC AGENT; INSULIN;

ACCELEROMETER; ADULT; AGED; ARTICLE; ASSOCIATION; BASAL METABOLIC RATE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; ENERGY EXPENDITURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; EXERCISE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; EXERCISE; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INSULIN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; TIME FACTORS;

EID: 84921783966     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006276     Document Type: Article

References (42)

1. Gardner DG, Chen S, Glenn DJ, et al. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 2007;49:419-26.
2. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-93.
3. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
4. Alehagen U, Lindstedt G, Levin LA, et al. Risk of cardiovascular death in elderly patients with possible heart failure. B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population. Int J Cardiol 2005;100:125-33.
5. Kroon MH, van den Hurk K, Alssema M, et al. Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: an 8-year follow-up of the Hoorn Study. Diabetes Care 2012;35:2510-14.
6. Olsen MH, Wachtell K, Tuxen C, et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004;22:1597-604.
7. Schirmer H, Omland T. Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Tromsø Study. Eur Heart J 1999;20:755-63.
8. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600.
9. Koizumi M, Watanabe H, Kaneko Y, et al. Impact of obesity on plasma B-type natriuretic peptide levels in Japanese community-based subjects. Heart Vessels 2012;27:287-94.
10. Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;46:660-6.
11. Hamilton MT, Hamilton DG, Zderic TW. Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Diabetes 2007;56:2655-67.
12. Avery L, Flynn D, van Wersch A, et al. Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions. Diabetes Care 2012;35:2681-9.
13. Barletta G, Stefani L, Del Bene R, et al. Effects of exercise on natriuretic peptides and cardiac function in man. Int J Cardiol 1998;65:217-25.
14. Nielsen HB, De Palo EF, Meneghetti M, et al. Circulating immunoreactive proANP1-30 and proANP31-67 responses to acute exercise. Regul Pept 2001;99:203-7.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62-9.
16. Levine JA. Non-exercise activity thermogenesis (NEAT). Nutr Rev 2004;62:S82-97.
17. Oshima Y, Kawaguchi K, Tanaka S, et al. Classifying household and locomotive activities using a triaxial accelerometer. Gait Posture 2010;31:370-4.
18. Ohkawara K, Oshima Y, Hikihara Y, et al. Real-time estimation of daily physical activity intensity by a triaxial accelerometer and a gravity-removal classification algorithm. Br J Nutr 2011;105:1681-91.
19. Ganpule AA, Tanaka S, Ishikawa-Takata K, et al. Interindividual variability in sleeping metabolic rate in Japanese subjects. Eur J Clin Nutr 2007;61:1256-61.
20. [No authors listed]. Energy and protein requirements. Report of a joint FAO/WHO/UNU Expert Consultation. World Health Organ Tech Rep Ser 1985;724:1-206.
21. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
22. Mongia SK, La'ulu SL, Apple FS, et al. Performance characteristics of the Architect brain natriuretic peptide (BNP) assay: a two site study. Clin Chim Acta 2008;391:102-5.
23. Neeland IJ, Winders BR, Ayers CR, et al. Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. J Am Coll Cardiol 2013;62:752-60.
24. Chainani-Wu N, Weidner G, Purnell DM, et al. Relation of B-type natriuretic peptide levels to body mass index after comprehensive lifestyle changes. Am J Cardiol 2010;105:1570-6.
25. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-5.
26. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004;164:2247-52.
27. Dessì-Fulgheri P, Sarzani R, Tamburrini P, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens 1997;15:1695-9.
28. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005;112:2163-8.
29. Costello-Boerrigter LC, Burnett JC Jr. A new role for the natriuretic peptides: metabolic regulators of the adipocyte. J Am Coll Cardiol 2009;53:2078-9.
30. Sengenès C, Berlan M, De Glisezinski I, et al. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 2000;14:1345-51.
31. Miyashita K, Itoh H, Tsujimoto H, et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 2009;58:2880-92.
32. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070-7.
33. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
34. Moro C, Klimcakova E, Lolmède K, et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 2007;50:1038-47.
35. Bordicchia M, Liu D, Amri EZ, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012;122:1022-36.
36. Engeli S, Birkenfeld AL, Badin PM, et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest 2012;122:4675-9.
37. Polak J, Kotrc M, Wedellova Z, et al. Lipolytic effects of B-type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls. J Am Coll Cardiol 2011;58:1119-25.
38. Tekes S, Cikim AS. The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension. J Hum Hypertens 2007;21:546-50.
39. Plasqui G, Bonomi AG, Westerterp KR. Daily physical activity assessment with accelerometers: new insights and validation studies. Obes Rev 2013;14:451-62.
40. Midorikawa T, Tanaka S, Kaneko K, et al. Evaluation of low-intensity physical activity by triaxial accelerometry. Obesity 2007;15:3031-8.
41. Ekelund U, Sjöström M, Yngve A, et al. Physical activity assessed by activity monitor and doubly labeled water in children. Med Sci Sports Exerc 2001;33:275-81.
42. Leenders NY, Sherman WM, Nagaraja HN. Energy expenditure estimated by accelerometry and doubly labeled water: do they agree? Med Sci Sports Exerc 2006;38:2165-72.